Publications by authors named "Michael Garshick"

Article Synopsis
  • Inflammatory bowel disease (IBD) can lead to a rare but serious condition called pericarditis, which causes inflammation of the heart's outer lining and is linked to significant health risks.
  • A study identified that among over 3 million IBD patients from 2011 to 2020, about 0.28% experienced pericarditis, especially those with additional autoimmune conditions like lupus or rheumatoid arthritis.
  • IBD patients who developed pericarditis had a higher risk of complications and inpatient mortality, highlighting the need for healthcare providers to recognize this connection and monitor at-risk patients closely.
View Article and Find Full Text PDF
Article Synopsis
  • The skin and cardiovascular systems are interconnected, with various cardiovascular diseases linked to specific skin manifestations.
  • Inflammatory skin conditions, like psoriasis, can lead to serious cardiovascular and metabolic health issues, while some cardiovascular medications may cause adverse skin reactions.
  • This review emphasizes the importance of integrating dermatology and cardiology insights for effective diagnosis and management of patients experiencing both skin and cardiovascular problems.
View Article and Find Full Text PDF

The Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) is a nonprofit organization whose mission is to optimize the clinical care of patients with psoriatic disease through multidisciplinary collaboration models. The PPACMAN 2021 Annual Meeting was held virtually on December 11, 2021. In all, 50 stakeholders participated in the meeting including dermatologists, rheumatologists, cardiologists, clinical researchers, patient advocacy representatives, and industry representatives.

View Article and Find Full Text PDF

The strong association between lipoprotein (a) [Lp(a)] and atherosclerotic cardiovascular disease has led to considerations of Lp(a) being a potential target for mitigating residual cardiovascular risk. While approximately 20 % of the population has an Lp(a) level greater than 50 mg/dL, there are no currently available pharmacological lipid-lowering therapies that have demonstrated substantial reduction in Lp(a). Novel therapies to lower Lp(a) include antisense oligonucleotides and small-interfering ribonucleic acid molecules and have shown promising results in phase 2 trials.

View Article and Find Full Text PDF

Purpose Of Review: Targeting traditional cardiovascular risk factors is effective in reducing recurrent cardiovascular events, yet the presence of residual cardiovascular risk due to underlying systemic inflammation is a largely unaddressed opportunity. This review aims to comprehensively assess the evolving role of colchicine as a therapeutic approach targeting residual inflammatory risk in the context of those with coronary artery disease (CAD).

Recent Findings: Inflammation plays a significant role in promoting atherosclerosis, and targeting anti-inflammatory pathways has the potential to decrease cardiovascular events.

View Article and Find Full Text PDF

Background: Cardiometabolic risk factors diabetes, obesity, and hypertension are highly prevalent and contribute to increased cardiovascular disease (CVD). Endothelial dysfunction precedes CVD development. The current study aimed to investigate the EC transcriptome among individuals with varying degree of cardiometabolic risk.

View Article and Find Full Text PDF
Article Synopsis
  • JAK inhibitors are effective for treating certain skin conditions but carry a FDA warning due to potential risks, including cardiovascular events and infections, based on data primarily from rheumatoid arthritis patients.
  • The study aimed to assess the risks associated with JAK inhibitors specifically in patients with dermatologic conditions, focusing on mortality and major adverse events.
  • Data from phase 3 clinical trials were analyzed using systematic review methodologies to evaluate the safety of these treatments in dermatology, with results derived from 35 randomized trials.
View Article and Find Full Text PDF

This review summarizes the evaluation for underlying rheumatic conditions in patients presenting with acute pericarditis, treatment considerations for specific rheumatic conditions, and the role of imaging in diagnosis and monitoring. Pericarditis may be one of the initial presentations of a rheumatic disease or identified in a patient with known rheumatic disease. There is also growing evidence for using anti-inflammatory and immunosuppressive agents for treating recurrent pericarditis, which can overlap with the treatment of rheumatic diseases.

View Article and Find Full Text PDF

Purpose Of Review: Pericarditis complicates pregnancy planning, pregnancy, or the postpartum period, and the management approach requires special considerations. Here, we aim to summarize the latest research, diagnostic, and treatment strategies.

Recent Findings: Physiologic cardiovascular (CV) adaptations occurring during pregnancy complicate diagnosis, but for most patients, an electrocardiogram (ECG) and transthoracic echocardiogram (TTE) are sufficient to diagnosis pericarditis in the appropriate clinical context.

View Article and Find Full Text PDF

Immune-mediated systemic inflammatory conditions (IMIDs) are associated with an increased risk of atherosclerosis and adverse cardiovascular (CV) events secondary to pathogenic inflammation and derangements in the innate and adaptive immune responses inherent to the underlying rheumatic diseases. As the intersection of cardio-rheumatology continues to expand, a multi-disciplinary approach must be considered to optimize clinical outcomes and long-term survival. This review will highlight acute cardiac manifestations of systemic inflammatory diseases and propose a clinically relevant framework for diagnosis, management, and the role of integrated multimodality imaging.

View Article and Find Full Text PDF